Elevation Oncology, Inc. (ELEV) Research

Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.

Market snapshot

Symbol
ELEV
Price
$0.37
Day change
-2.12%
Market cap
$21.6M
P/E ratio
-0.88x
52-week range
0.221-3.09
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$9.00

Peer companies

  • AnPac Bio-Medical Science Co., Ltd. (ANPC)
  • Dominari Holdings Inc. (DOMH)
  • Kineta, Inc. (KA)
  • LakeShore Biopharma Co., Ltd (LSB)
  • MEI Pharma, Inc. (MEIP)
  • MetaVia Inc. (MTVA)
  • PHAXIAM Therapeutics S.A. (PHXM)
  • Pieris Pharmaceuticals, Inc. (PIRS)

Recent insider activity

  • Sandler Alan B. — D-Return (35000 shares) on 2025-07-23
  • Sandler Alan B. — D-Return (55000 shares) on 2025-07-23
  • Sandler Alan B. — D-Return (35000 shares) on 2025-07-23
  • Mootz Darcy — D-Return (55000 shares) on 2025-07-23
  • Mootz Darcy — D-Return (35000 shares) on 2025-07-23

Open Elevation Oncology, Inc. (ELEV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.